The primary endpoint of the study deals with the efficacy of the combination of enzalutamide monotherapy and modern Hypo-EBRT, in terms of reduction of PSA levels, in patients with localized intermediate-risk prostate cancer, as used in similar trials (24–26, 38). This evidence concerns the gene KLK3 and prostate cancer.